|
1
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Abate D, Abbasi N, Abbastabar H,
Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I,
et al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2017:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 5:1749–1768. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marquardt JU, Andersen JB and Thorgeirsson
SS: Functional and genetic deconstruction of the cellular origin in
liver cancer. Nat Rev Cancer. 15:653–667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gordon AC: Ectopic anus in the adult. Br J
Surg. 74:6541987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vitale A, Cabibbo G, Iavarone M, Viganò L,
Pinato DJ, Ponziani FR, Lai Q, Casadei-Gardini A, Celsa C, Galati
G, et al: Personalised management of patients with hepatocellular
carcinoma: A multiparametric therapeutic hierarchy concept. Lancet
Oncol. 24:e312–e322. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Couri T and Pillai A: Goals and targets
for personalized therapy for HCC. Hepatol Int. 13:125–137. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
European Association for the Study of the
Liver, . EASL clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng W, Chen F, Li Y and Xu L: Development
of a clinical scoring model to predict the overall and relapse-free
survival of patients with hepatocellular carcinoma following a
hepatectomy. Mol Clin Oncol. 19:872023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roayaie S, Obeidat K, Sposito C, Mariani
L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M and
Mazzaferro V: Resection of hepatocellular cancer ≤2 cm: Results
from two Western centers. Hepatology. 57:1426–1435. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song P, Tobe RG, Inagaki Y, Kokudo N,
Hasegawa K, Sugawara Y and Tang W: The management of hepatocellular
carcinoma around the world: A comparison of guidelines from 2001 to
2011. Liver Int. 32:1053–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
She S, Xiang Y, Yang M, Ding X, Liu X, Ma
L, Liu Q, Liu B, Lu Z, Li S, et al: C-reactive protein is a
biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int
J Oncol. 47:543–554. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Farinati F, Marino D, De Giorgio M, Baldan
A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA,
Benvegnù L, et al: Diagnostic and prognostic role of
alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am
J Gastroenterol. 101:524–532. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cucchetti A, Piscaglia F, Grigioni AD,
Ravaioli M, Cescon M, Zanello M, Grazi GL, Golfieri R, Grigioni WF
and Pinna AD: Preoperative prediction of hepatocellular carcinoma
tumour grade and micro-vascular invasion by means of artificial
neural network: A pilot study. J Hepatol. 52:880–888. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan AWH, Zhong J, Berhane S, Toyoda H,
Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, et al:
Development of pre and post-operative models to predict early
recurrence of hepatocellular carcinoma after surgical resection. J
Hepatol. 69:1284–1293. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moazzam Z, Alaimo L, Endo Y, Lima HA,
Shaikh CF, Ratti F, Marques HP, Cauchy F, Lam V, Poultsides GA, et
al: Variations in textbook oncologic outcomes after curative-intent
resection: Early versus intermediate hepatocellular carcinoma based
on barcelona clinic liver cancer criteria and child-pugh
classification. Ann Surg Oncol. 30:750–759. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
R Core Team R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2021, URL. http://www.R-project.org/
|
|
18
|
Wang M, Devarajan K, Singal AG, Marrero
JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, et
al: The doylestown algorithm: A test to improve the performance of
AFP in the detection of hepatocellular carcinoma. Cancer Prev Res
(Phila). 9:172–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schwartz M: A biomathematical approach to
clinical tumor growth. Cancer. 14:1272–1294. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tateishi R, Shiina S, Yoshida H, Teratani
T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T and Omata M:
Prediction of recurrence of hepatocellular carcinoma after curative
ablation using three tumor markers. Hepatology. 44:1518–1527. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wen T, Jin C, Facciorusso A, Donadon M,
Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, et al:
Multidisciplinary management of recurrent and metastatic
hepatocellular carcinoma after resection: An international expert
consensus. Hepatobiliary Surg Nutr. 7:353–371. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peterson ML, Ma C and Spear BT: Zhx2 and
Zbtb20: Novel regulators of postnatal alpha-fetoprotein repression
and their potential role in gene reactivation during liver cancer.
Semin Cancer Biol. 21:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rebouissou S and Nault JC: Advances in
molecular classification and precision oncology in hepatocellular
carcinoma. J Hepatol. 72:215–229. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang W and Wei C: Advances in the early
diagnosis of hepatocellular carcinoma. Genes Dis. 7:308–319. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singal AG, Kanwal F and Llovet JM: Global
trends in hepatocellular carcinoma epidemiology: Implications for
screening, prevention and therapy. Nat Rev Clin Oncol. 20:864–884.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 Practice
guidance by the American association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu X, Li S, Xu Y, Zhang Y, Ma W, Liang C,
Lu H, Ji Y, Liu C, Chen D and Li J: Androgen maintains intestinal
homeostasis by inhibiting BMP signaling via intestinal stromal
cells. Stem Cell Reports. 18:4102023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ferrer-Fàbrega J, Forner A, Liccioni A,
Miquel R, Molina V, Navasa M, Fondevila C, García-Valdecasas JC,
Bruix J and Fuster J: Prospective validation of ab initio liver
transplantation in hepatocellular carcinoma upon detection of risk
factors for recurrence after resection. Hepatology. 63:839–849.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsilimigras DI, Sahara K, Moris D, Hyer
JM, Paredes AZ, Bagante F, Merath K, Farooq AS, Ratti F, Marques
HP, et al: Effect of surgical margin width on patterns of
recurrence among patients undergoing R0 hepatectomy for T1
hepatocellular carcinoma: An international multi-institutional
analysis. J Gastrointest Surg. 24:1552–1560. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Han L, Xiao B, Li X and Ye Z: A
predictive nomogram of early recurrence for patients with
AFP-negative hepatocellular carcinoma underwent curative resection.
Diagnostics (Basel). 12:10732022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan X, Li Y, Qin W, Liao J, Fan J, Xie Y,
Wang Z, Li S and Liao W: Radiomics model based on contrast-enhanced
computed tomography imaging for early recurrence monitoring after
radical resection of AFP-negative hepatocellular carcinoma. BMC
Cancer. 24:7002024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gan W, Huang JL, Zhang MX, Fu YP, Yi Y,
Jing CY, Fan J, Zhou J and Qiu SJ: New nomogram predicts the
recurrence of hepatocellular carcinoma in patients with negative
preoperative serum AFP subjected to curative resection. J Surg
Oncol. 117:1540–1547. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao S, Yu X, Shan Y, Fan R, Wu S and Lu C:
Albumin-bilirubin (ALBI) and monocyte to lymphocyte ratio
(MLR)-based nomogram model to predict tumor recurrence of
AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma.
8:1355–1365. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang J, Liu FC, Li L, Zhou WP, Jiang BG
and Pan ZY: Nomograms to predict the long-time prognosis in
patients with alpha-fetoprotein negative hepatocellular carcinoma
following radical resection. Cancer Med. 9:2791–2802. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang D, Hanna DL, Usher J, LoCoco J,
Chaudhari P, Lenz HJ, Setiawan VW and El-Khoueiry A: Impact of sex
on the survival of patients with hepatocellular carcinoma: A
Surveillance, Epidemiology, and End Results analysis. Cancer.
120:3707–3716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goh BK, Teo JY, Chan CY, Lee SY, Jeyaraj
P, Cheow PC, Chow PK, Ooi LL and Chung AY: Importance of tumor size
as a prognostic factor after partial liver resection for solitary
hepatocellular carcinoma: Implications on the current AJCC staging
system. J Surg Oncol. 113:89–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB,
Ha TY, Song GW, Jung DH and Lee SG: The impact of tumor size on
long-term survival outcomes after resection of solitary
hepatocellular carcinoma: Single-institution experience with 2558
patients. J Gastrointest Surg. 19:1281–1290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li J, Li Z, Hao S, Wang J, Chen W, Dai S,
Hou Z, Chen B, Zhang Y and Liu D: Inversed albumin-to-globulin
ratio and underlying liver disease severity as a prognostic factor
for survival in hepatocellular carcinoma patients undergoing
transarterial chemoembolization. Diagn Interv Radiol. 29:520–528.
2023.PubMed/NCBI
|
|
40
|
Yan H, Chen S, Qiong Y and Cai L:
Preoperative prealbumin-to-fibrinogen ratio to predict survival
outcomes in hepatocellular carcinoma patients after hepatic
resection. J Med Biochem. 41:290–298. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li J, Lan Z, Liao W, Horner JW, Xu X, Liu
J, Yoshihama Y, Jiang S, Shim HS, Slotnik M, et al: Histone
demethylase KDM5D upregulation drives sex differences in colon
cancer. Nature. 619:632–639. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abdel-Hafiz HA, Schafer JM, Chen X, Xiao
T, Gauntner TD, Li Z and Theodorescu D: Y chromosome loss in cancer
drives growth by evasion of adaptive immunity. Nature. 619:624–631.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kwon H, Schafer JM, Song NJ, Kaneko S, Li
A, Xiao T, Ma A, Allen C, Das K, Zhou L, et al: Androgen conspires
with the CD8+ T cell exhaustion program and contributes
to sex bias in cancer. Sci Immunol. 7:eabq26302022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang X, Cheng L, Gao C, Chen J, Liao S,
Zheng Y, Xu L, He J, Wang D, Fang Z, et al: Androgen signaling
contributes to sex differences in cancer by inhibiting NF-κB
activation in T cells and suppressing antitumor immunity. Cancer
Res. 83:906–921. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu F, Yuan JH, Huang JF, Yang F, Wang TT,
Ma JZ, Zhang L, Zhou CC, Wang F, Yu J, et al: Long noncoding RNA
FTX inhibits hepatocellular carcinoma proliferation and metastasis
by binding MCM2 and miR-374a. Oncogene. 35:5422–5434. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shinkawa H, Tanaka S, Takemura S, Ishihara
T, Yamamoto K and Kubo S: Tumor size drives the prognosis after
hepatic resection of solitary hepatocellular carcinoma without
vascular invasion. J Gastrointest Surg. 24:1040–1048. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dai CY, Lin CY, Tsai PC, Lin PY, Yeh ML,
Huang CF, Chang WT, Huang JF, Yu ML and Chen YL: Impact of tumor
size on the prognosis of hepatocellular carcinoma in patients who
underwent liver resection. J Chin Med Assoc. 81:155–163. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shimada S, Kamiyama T, Orimo T, Nagatsu A,
Asahi Y, Sakamoto Y, Kamachi H and Taketomi A: Long-term prognostic
factors of patients with hepatocellular carcinoma who survive over
10 years after hepatectomy. J Surg Oncol. 121:1209–1217. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brennan PN, Dillon JF and Tapper EB:
Gamma-glutamyl transferase (γ-GT)-an old dog with new tricks? Liver
Int. 42:9–15. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Moreira AJ, Rodrigues GR, Bona S, Fratta
LX, Weber GR, Picada JN, Dos Santos JL, Cerski CT, Marroni CA and
Marroni NP: Ductular reaction, cytokeratin 7 positivity, and
gamma-glutamyl transferase in multistage hepatocarcinogenesis in
rats. Protoplasma. 254:911–920. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
McCaffrey P, Gilmore DH and Beringer TR:
Relief care and risk of death in psychogeriatric patients. BMJ.
298:15221989. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Z, Song P, Xia J, Inagaki Y, Tang W
and Kokudo N: Can gamma-glutamyl transferase levels contribute to a
better prognosis for patients with hepatocellular carcinoma? Drug
Discov Ther. 8:134–138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang L, Mo Z, Hu Z, Zhang L, Qin S, Qin X
and Li S: Diagnostic value of fibrinogen to prealbumin ratio and
gamma-glutamyl transpeptidase to platelet ratio in the progression
of AFP-negative hepatocellular carcinoma. Cancer Cell Int.
20:772020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Carr BI, Guerra V, Giannini EG, Farinati
F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M,
Borzio F, et al: Low alpha-fetoprotein HCC and the role of GGTP.
Int J Biol Markers. 29:e395–e402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Palumbo JS, Kombrinck KW, Drew AF, Grimes
TS, Kiser JH, Degen JL and Bugge TH: Fibrinogen is an important
determinant of the metastatic potential of circulating tumor cells.
Blood. 96:3302–3309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Son HJ, Park JW, Chang HJ, Kim DY, Kim BC,
Kim SY, Park SC, Choi HS and Oh JH: Preoperative plasma
hyperfibrinogenemia is predictive of poor prognosis in patients
with nonmetastatic colon cancer. Ann Surg Oncol. 20:2908–2913.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jiang HG, Li J, Shi SB, Chen P, Ge LP,
Jiang Q and Tang XP: Value of fibrinogen and D-dimer in predicting
recurrence and metastasis after radical surgery for non-small cell
lung cancer. Med Oncol. 31:222014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hefler-Frischmuth K, Lafleur J, Hefler L,
Polterauer S, Seebacher V, Reinthaller A and Grimm C: Plasma
fibrinogen levels in patients with benign and malignant ovarian
tumors. Gynecol Oncol. 136:567–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kinoshita A, Onoda H, Imai N, Iwaku A,
Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M and
Tajiri H: Elevated plasma fibrinogen levels are associated with a
poor prognosis in patients with hepatocellular carcinoma. Oncology.
85:269–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tanaka N, Kikuchi E, Matsumoto K, Hayakawa
N, Ide H, Miyajima A, Nakamura S and Oya M: Prognostic value of
plasma fibrinogen levels in patients with localized upper tract
urothelial carcinoma. BJU Int. 111:857–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
